FrancophonIA/ELRC3.0 huggingface dataset:
English: In 2006, an EMA expert meeting1 on FVIII products and inhibitor development concluded that there was a need to collect comparable clinical data on the immunogenicity of recombinant and plasmaderived FVIII products as a long-term objective.
Estonian: Euroopa Ravimiameti spetsialistide 2006. aasta kohtumisel1 VIII hüübimisfaktorit sisaldavate ravimite ja inhibiitorite tekke teemal otsustati, et pikaajalise eesmärgina on vaja koguda võrdlevaid kliinilisi andmeid rekombinantsete ning vereplasmast toodetud VIII hüübimisfaktorit sisaldavate ravimite immunogeensuse kohta.
English: However, the data presented by the MAH indicate that there are no significant changes in the posttranslational modifications, aggregation profile, specific activity or excipients since MA of Kogenate Bayer that might have increased the risk for inhibitor development over time.
Estonian: Samas näitavad müügiloa hoidja esitatud andmed, et pärast ravimi Kogenate Bayer müügiloa andmist ei ole olnud selliseid olulisi muutusi tõlgendusjärgsetes muudatustes, agregatsiooniprofiilis, spetsiifilises aktiivsuses ega abiainetes, mis oleksid võinud suurendada inhibiitorite tekke riski aja jooksul.
English: These two interventional studies were carried out as prospective, uncontrolled trials, for treatment of bleeding episodes in 37 PUPs and 23 MTPs with residual FVIII:C < 2 IU/dl.
Estonian: Nimetatud kaks sekkuvat kliinilist uuringut olid oma ülesehituselt prospektiivsed kontrollita uuringud verejooksu episoodide raviks 37-l varem mitteravitud patsiendil ja 23-l minimaalset ravi saanud patsiendil, kelle residuaalne VIII hüübimisfaktor:C oli < 2 RÜ/dl.
English: J. Med. 368, 231 (2013)) were made available and seemed to suggest that Kogenate Bayer/Helixate NexGen were associated with an increased risk of inhibitor development in previously untreated patients (PUPs) when compared to another recombinant antihaemophilic factor VIII, after adjustment for confounding factors.
Estonian: J. Med. 368, 231 (2013)) tulemused näitasid, et Kogenate Bayer / Helixate NexGen tekitasid võrreldes teise rekombinantse antihemofiilse VIII hüübimisfaktoriga pärast kohandamist faktormõjude suhtes inhibiitorite tekke suurema riski varem mitteravitud patsientidel.
English: Finally in support of the above mentioned clinical data, the MAH provided quality data with regards to the manufacturing process for Kogenate Bayer and Helixate Nexgen.
Estonian: Peale ülalmainitud kliiniliste andmete esitas müügiloa hoidja kvaliteediandmed ravimite Kogenate Bayer ja Helixate NexGen tootmisprotsessi kohta.
English: According to the MAH, since the Marketing Authorisations, 42 changes in the manufacturing process of KOGENATE Bayer have been introduced.
Estonian: Müügiloa hoidja esitatud andemete kohaselt on ravimi Kogenate Bayer tootmisprotsessis tehtud pärast müügiloa andmist kokku 42 muudatust.
English: In addition, the PRAC noted an update from the on-going EUHASS data, and results showed an inhibitor incidence for Kogenate Bayer and Helixate Nexgen comparable to other products: whereas no adjustment for known risk factors for inhibitor development could be performed due to the study design, the PRAC noted that the 95 % CIs of the point estimates of PUP inhibitor incidence were overlapping substantially between different products.
Estonian: Peale selle võttis ravimiohutuse riskihindamiskomitee arvesse ajakohastatud EUHASS-i andmeid, mis näitasid, et inhibiitorite teke ravimite Kogenate Bayer ja Helixate NexGen kasutamisel on võrreldav teiste ravimitega: kuigi uuringu ülesehituse tõttu ei olnud võimalik andmeid kohandada inhibiitorite tekke teadaolevate riskiteguritega, märkis ravimiohutuse riskihindamiskomitee, et inhibiitorite tekke punkthinnangute 95%-lised usalduspiirid erinevate ravimite korral olid varem mitteravitud patsientidel suures osas kattuvad.
English: Kogenate Bayer and Helixate NexGen are full-length recombinant human antihaemophilic factor VIII (octocog alfa) produced in baby hamster kidney (BHK) cells.
Estonian: Kogenate Bayer ja Helixate NexGen on täispikkuses rekombinantsed inimese antihemofiilsed VIII hüübimisfaktorid (alfaoktokog), mida toodetakse hamstripoegade neerurakkudest.
English: In addition, upon request from the PRAC, the MAH provided analyses of the overall results on the observed inhibitor incidence in the light of the study design and patient selection.
Estonian: Peale selle esitas müügiloa hoidja ravimiohutus riskihindamiskomitee nõudel inhibiitorite tekke esinemissageduse analüüsi tulenevalt uuringute ülesehitusest ja patsientide valikust.
English: • The PRAC noted that the efficacy of Kogenate Bayer/Helixate NexGen is not questioned and, on the basis of the available data, concluded that the current results do not confirm an increased risk of developing antibodies against Kogenate Bayer and Helixate NexGen when compared with other factor VIII products in PUPs with the bleeding disorder haemophilia A.
Estonian: • ravimiohutuse riskihindamiskomitee märkis, et Kogenate Bayeri / Helixate NexGeni efektiivsuses osas ei ole kahtlusi ning otsustas olemasolevate andmete alusel, et need ei kinnita varem mitteravitud veritsushäirega A-hemofiiliaga patsientidel antikehade tekke suuremat riski ravimite Kogenate Bayer ja Helixate NexGen suhtes võrreldes teiste VIII hüübimisfaktorit sisaldavate ravimitega;
English: Kogenate Bayer/Helixate NexGen are indicated for treatment and prophylaxis of bleeding in patients with hemophilia A (congenital factor VIII deficiency).
Estonian: Kogenate Bayer / Helixate NexGen on näidustatud verejooksu raviks ja profülaktikaks A-hemofiiliaga patsientidel (VIII hüübimisfaktori kaasasündinud vaegus).
English: • The PRAC considered the publication of the results of the RODIN/PedNet study, the preliminary findings from the European Haemophilia Safety Surveillance System (EUHASS) registry and all available data submitted from clinical trials, observational studies, published literature and quality data for Kogenate Bayer and Helixate NexGen with regards to its potential risk of inhibitor development in previously untreated patients (PUPs).
Estonian: • ravimiohutuse riskihindamiskomitee arutas RODIN-i/PedNet-i uuringu avaldatud tulemusi, Euroopa hemofiilia ohutuse jälgimise süsteemi (EUHASS) registri esialgseid tulemusi ning kõiki esitatud kliiniliste uuringute, vaatlusuuringute ja kirjanduses avaldatud olemasolevaid andmeid ning kvaliteediandmeid ravimite Kogenate Bayer ja Helixate NexGen kohta, mis puudutasid inhibiitorite tekke riski varem mitteravitud patsientidel;
English: The CHMP considered the below PRAC recommendation dated 5 December 2013 with regards to the procedure under Article 20 of Regulation (EC) No 726/2004 for Kogenate Bayer and Helixate NexGen.
Estonian: Inimravimite komitee arutas allolevat ravimiohutuse riskihindamiskomitee 5. detsembri 2013. aasta soovitust vastavalt ravimite Kogenate Bayer ja Helixate NexGen määruse (EÜ) nr 726/2004 artikli 20 kohasele menetlusele.
English: In one observational study, the incidence of inhibitor development in previously untreated patients with severe haemophilia A was 64/183 (37.7%) with Helixate NexGen (followed up to 75 exposure days).
Estonian: Ühes vaatlusuuringus oli inhibiitorite tekke esinemissagedus (kuni 75 ekspositsioonipäeva vältel) Helixate NexGeni kasutamisel varem mitteravitud raske A-hemofiiliaga patsientidel 37,7% (64/183).
English: In this context, the PRAC noted that Kogenate Bayer and Helixate Nexgen is potency labelled based on an one-stage clotting assay, in accordance with the approved quality documentation for the product, and not the chromogenic assay as per the European Pharmacopeia.
Estonian: Kvaliteedi osas märkis ravimiohutuse riskihindamiskomitee, et ravimite Kogenate Bayer ja Helixate NexGen tugevus on antud ravimite heakskiidetud kvaliteedidokumentide alusel määratud üheastmelise hüübimistestiga, mitte Euroopa farmakopöas ettenähtud kromogeense meetodi abil.
English: The objective of the RODIN/Pednet study was to examine the inhibitor development in PUPs with severe haemophilia A given recombinant or plasma-derived FVIII products.
Estonian: Uuringu RODIN/PedNet eesmärk oli hinnata inhibiitorite teket varem mitteravitud raske A-hemofiiliaga patsientidel, kes saavad ravi rekombinantse või vereplasmast toodetud VIII hüübimisfaktorit sisaldava ravimiga.
English: The PRAC considered results from the publication of the RODIN/PedNet study, the preliminary findings from the European Haemophilia Safety Surveillance System (EUHASS) registry and all available data submitted from clinical trials, observational studies, published literature as well as quality data for Kogenate Bayer and Helixate NexGen with regards to its potential risk of inhibitor development in previously untreated patients (PUPs) and minimally treated patients (MTPs).
Estonian: Ravimiohutuse riskihindamiskomitee arutas RODIN-i/PedNet-i uuringu avaldatud tulemusi, Euroopa hemofiilia ohutuse jälgimise süsteemi (EUHASS) registri esialgseid tulemusi ja kõiki esitatud kliiniliste uuringute, vaatlusuuringute, samuti kirjanduse andmeid ja kvaliteediandmeid ravimite Kogenate Bayer ja Helixate NexGen kohta, mis puudutasid inhibiitorite tekke riski varem mitteravitud ja minimaalset ravi saanud patsientidel.
English: The MAH provided data on the above-mentioned observational studies with regards to the risk of inhibitor development in PUPs receiving FVIII products, including KOGENATE Bayer/Helixate NexGen.
Estonian: Müügiloa hoidja esitas andmed eelmainitud vaatlusuuringute kohta, mis puudutasid inhibiitorite teket varem mitteravitud patsientidel, keda ravitakse VIII hüübimisfaktorit sisaldavate ravimitega, sealhulgas ravimitega Kogenate Bayer / Helixate NexGen.
English: • The PRAC considered though that the frequency for inhibitor development in PUPs should be amended from “common” to “very common” in the section 4.8 of the SmPC and also recommended that the product information should be updated to reflect the most recent results from the RODIN study.
Estonian: • ravimiohutuse riskihindamiskomitee otsustas, et inhibiitorite tekke esinemissagedus varem mitteravitud patsientidel tuleb ravimi omaduste kokkuvõtte lõigus 4.8 muuta esinemissageduselt „sage“ esinemissageduseks „väga sage“ ning soovitas rutiinse riskivähendamismeetmena samuti ajakohastada ravimiteavet uuringu RODIN tulemustega.
English: Development of inhibitors against FVIII is the most significant complication of replacement therapy for haemophilia A. These antibodies inactivate the pro-coagulant activity of FVIII and inhibit patients' response to FVIII replacement therapy which may result in life-threatening bleedings and sequelae.
Estonian: Nimetatud antikehad inaktiveerivad VIII hüübimisfaktori hüübimist soodustava toime ning vähendavad patsientide ravivastust VIII hüübimisfaktori asendusravile, mille tagajärjel võivad tekkida eluohtlikud verejooksud ja muud tüsistused.
English: Haemophilia centres in Western Europe and major haemophilia centres in North America enrolled a total of 60 PUPs/MTPs without pre-existing inhibitors in two studies (200021EU and 100074US).
Estonian: Lääne-Euroopa ja Põhja-Ameerika suured hemofiiliakeskused kaasasid kahte uuringusse (200021EU ja 100074US) kokku 60 varem mitteravitud ja minimaalset ravi saanud patsienti, kellel ei esinenud uuringu algtasemel inhibiitoreid.
English: Five out of 37 (14%) PUP and 4 out of 23 (17%) MTP patients treated with Helixate NexGen developed inhibitors within 20 ED (exposure days).
Estonian: 20 ekspositsioonipäeva ajal tekkisid inhibiitorid varem mitteravitud 37 patsiendist 5-l (14%) ja minimaalset ravi saanud 23 patsiendist 4-l (17%), keda raviti Helixate NexGeniga.
English: The PRAC therefore concluded that the benefit-risk balance of Kogenate Bayer and Helixate NexGen indicated as for the treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency) remains favourable subject to the changes to the product information agreed.
Estonian: Seetõttu otsustas ravimiohutuse riskihindamiskomitee, et ravimite Kogenate Bayer ja Helixate NexGen, mis on näidustatud verejooksu raviks ja profülaktikaks A-hemofiiliaga patsientidel (VIII hüübimisfaktori kaasasündinud vaegus), kasulikkuse ja riski tasakaal on endiselt soodne, kui ravimiteabesse viiakse sisse kokkulepitud muudatused.
English: Having noted the above, the PRAC concluded that the benefit-risk balance of Kogenate Bayer and Helixate NexGen indicated as for the treatment and prophylaxis of bleeding in patients with hemophilia A (congenital factor VIII deficiency) remains favourable subject to the changes to the product information agreed.
Estonian: Ülaltoodut arvesse võttes otsustas ravimiohutuse riskihindamiskomitee, et ravimite Kogenate Bayer ja Helixate NexGen, mis on näidustatud verejooksu raviks ja profülaktikaks A-hemofiiliaga patsientidel (VIII hüübimisfaktori kaasasündinud vaegus), kasulikkuse ja riski tasakaal on endiselt soodne, kui ravimiteabesse viiakse sisse kokkulepitud muudatused.
English: The MAH will continue to support the RODIN/PedNet registry as well as the EUHASS registry, as per current obligations defined in the RMP, to further investigate individual risk factors for inhibitor development and risk mitigation in PUPs.
Estonian: Müügiloa hoidja jätkab riskijuhtimiskavas ettenähtud kohustustena RODIN-i/PedNet-i ja EUHASS-i patsiendiregistrite toetamist, et uurida inhibiitorite tekke individuaalseid riskitegureid ja riskivähendamise meetmeid varem mitteravitud patsientidel.
English: The efficacy of Kogenate Bayer/Helixate NexGen is recognised and the PRAC reviewed the data related to inhibitor development in PUPs and MTPs.
Estonian: Ravimite Kogenate Bayer / Helixate NexGen efektiivsus on üldiselt tunnustatud, mistõttu vaatas ravimiohutuse riskihindamiskomitee läbi üksnes andmed, mis puudutasid inhibiitorite teket varem mitteravitud patsientidel ja minimaalset ravi saanud patsientidel.
English: In view of the above, the PRAC agreed that the current evidence does not confirm an increased risk of developing antibodies against Kogenate Bayer and Helixate NexGen when compared with other factor VIII products in PUPs with the bleeding disorder haemophilia A. However the PRAC considered that the frequency for inhibitor development in PUPs should be amended from “common” to “very common” in the section 4.8 of the SmPC and also recommended that the product information should be updated with results from the RODIN study as part of the routine risk minimisation activities.
Estonian: Siiski otsustas ravimiohutuse riskihindamiskomitee, et inhibiitorite tekke esinemissagedus varem mitteravitud patsientidel tuleb ravimi omaduste kokkuvõtte lõigus 4.8 muuta esinemissageduselt „sage“ esinemissageduseks „väga sage“ ning soovitas rutiinse riskivähendamise meetmena samuti ajakohastada ravimiteavet RODIN-i uuringu tulemustega.
English: Packaging Content (concentration) Package size
Estonian: Ravimvorm Manustamistee Pakendi iseloomustus Pakendi sisu (kontsentratsioon)
English: Cyramza received a marketing authorisation valid throughout the EU on 19 December 2014.
Estonian: Cyramza on saanud müügiloa, mis kehtib kogu ELis, 19. detsembril 2014.
English: What measures are being taken to ensure the safe and effective use of Cyramza?
Estonian: Mis meetmed võetakse, et tagada Cyramza ohutu ja efektiivne kasutamine?
English: Although the effects were modest, the size of the benefit was considered clinically relevant given the normally poor prognosis in these patients.
Estonian: Kuigi ravimi mõju oli tagasihoidlik, peeti selle kasulikkust kliiniliselt oluliseks, arvestades nende patsientide üldiselt halba prognoosi.
English: Further information on Cyramza can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/cyramza.
Estonian: Lisateave Cyramza kohta on ameti veebilehel: ema.europa.eu/medicines/human/EPAR/cyramza.
English: Cyramza (ramucirumab)
Estonian: Cyramza (ramutsirumaab)
English: The European Medicines Agency decided that Cyramza's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et Cyramza kasulikkus on suurem kui sellega kaasnevad riskid ja ravimi kasutamise võib ELis heaks kiita.
English: Other information about Cyramza
Estonian: Muu teave Cyramza kohta
English: As for all medicines, data on the use of Cyramza is continuously monitored.
Estonian: Nagu kõigi ravimite puhul, tehakse Cyramza kasutamise kohta pidevat järelevalvet.
English: Why is Cyramza authorised in the EU?
Estonian: Miks Cyramza ELis heaks kiideti?
English: The benefit was smaller when Cyramza was given on its own, but this could still be an option when treatment with paclitaxel is not considered appropriate.
Estonian: Kasulikkus oli väiksem Cyramza ainuravimina kasutamisel, kuid see võib sellegipoolest olla ravivõimalus, kui ravi paklitakseeliga ei peeta sobivaks.
English: What is Cyramza and what is it used for?
Estonian: Mis on Cyramza ja milleks seda kasutatakse?
English: Side effects reported with Cyramza are carefully evaluated and any necessary action taken to protect patients.
Estonian: Cyramza kõrvalnähte hinnatakse hoolikalt ja patsientide kaitseks võetakse vajalikke meetmeid.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Cyramza have been included in the summary of product characteristics and the package leaflet.
Estonian: Cyramza ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: The safety profile of Cyramza is in line with that expected for other medicines blocking VEGFR activity and is considered manageable.
Estonian: Cyramza ohutusprofiil on kooskõlas teiste VEGFR-i toimet blokeerivate ravimite eeldatava ohutusprofiiliga ja seda peetakse hallatavaks.
English: By attaching to VEGFR, ramucirumab blocks this action, reducing the blood supply to the tumour and so slowing the growth of the cancer.
Estonian: VEGFR-iga seondudes blokeerib ramutsirumaab selle toime, vähendades kasvaja verevarustust ja aeglustades seega vähi kasvu.
English: What are the risks associated with Cyramza?
Estonian: Mis riskid Cyramzaga kaasnevad?
English: It can only be obtained with a prescription and treatment should be started and supervised by a specialist who has experience in the treatment of cancer.
Estonian: Ravi peab algama ja toimuma vähiravis kogenud arsti järelevalve all.
English: Cyramza is a cancer medicine used to treat adult patients with:
Estonian: Cyramza on vähiravim, mida kasutatakse järgmiste seisunditega täiskasvanud patsientide raviks:
English: The most common side effects with Cyramza (which may affect more than 1 in 10 people) include tiredness or weakness, leucopenia (low white blood cell counts), neutropenia (low counts of a particular type of white blood cell), diarrhoea, nosebleeds and stomatitis (inflammation of the lining of the mouth).
Estonian: Cyramza kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) on väsimus või nõrkus, leukopeenia (leukotsüütide ehk vere valgeliblede vähesus), neutropeenia (neutrofiilide ehk teatud valgeliblede vähesus), kõhulahtisus, ninaverejooksud ja stomatiit (suu limaskesta põletik).
English: For the full list of side effects of Cyramza, see the package leaflet.
Estonian: Cyramza kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: When used for lung cancer, Cyramza must not be used when there is a cavity in the cancer or if the cancer is close to a major blood vessel.
Estonian: Cyramzat ei tohi kasutada kopsuvähi raviks õõnsusega kasvaja korral või juhul, kui kasvaja paikneb suure veresoone lähedal.
English: The Agency noted that Cyramza prolonged the lives of patients with gastric and gastro-oesophageal junction cancer when it was given with paclitaxel.
Estonian: Amet märkis, et Cyramza pikendas maovähi ja gastroösofageaalliiduse vähiga patsientide elu, kui seda kasutati kombinatsioonis paklitakseeliga.
English: How does Cyramza work?
Estonian: Kuidas Cyramza toimib?
English: Cyramza is used on its own in patients with a high blood level of a protein called alpha fetoprotein (AFP) and who have been previously treated with sorafenib.
Estonian: Cyramzat kasutatakse ainuravimina patsientidel, kellel on veres suur alfafetoproteiini (AFP; teatud valk) sisaldus ja keda on varem ravitud sorafeniibiga.
English: Cyramza is used in combination with docetaxel in patients whose disease has worsened despite treatment with medicines containing platinum;
Estonian: Cyramzat kasutatakse kombinatsioonis dotsetakseeliga patsientidel, kellel haigus on pärast ravi plaatinapreparaati sisaldavate ravimitega süvenenud;
English: Treatment should continue for as long as the patient benefits from it. For more information about using Cyramza, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Cyramza kasutamise kohta saate pakendi infolehelt või küsige oma arstilt või apteekrilt.
English: Similarly, in another study in 355 patients, those treated with Cyramza plus best supportive care lived longer than patients receiving placebo plus best supportive care (an average of 5.2 months versus 3.8 months, respectively).
Estonian: Teises, 355 patsiendiga uuringus elasid Cyramzaga ravitud ja parimat toetavat ravi saanud patsiendid samuti oluliselt kauem kui platseeboga ravitud ja parimat toetavat ravi saanud patsiendid (keskmiselt vastavalt 5,2 ja3,8 kuud).
English: The active substance in Cyramza, ramucirumab, is a monoclonal antibody (a type of protein) designed to attach to vascular endothelial growth factor receptor (VEGFR), a protein present at high levels in tumours.
Estonian: Cyramza toimeaine ramutsirumaab on monoklonaalne antikeha (teatud valk), mis on kavandatud seonduma vaskulaarse endoteeli kasvufaktori retseptoriga (VEGFR), mis on valk, mida leidub kasvajates suures koguses.
English: How is Cyramza used?
Estonian: Kuidas Cyramzat kasutatakse?
English: The dose of Cyramza and how often it is given depends on the patient's weight and the condition being treated.
Estonian: Cyramza annus ja manustamissagedus sõltuvad patsiendi kehamassist ja ravitavast haigusseisundist.
English: • advanced gastric cancer (cancer of the stomach) or cancer of the area where the gullet (oesophagus) enters the stomach (known as gastro-oesophageal junction adenocarcinoma).
Estonian: • kaugelearenenud maovähk või söögitoru makku suubumise piirkonna (lävisesuudme) vähk (gastroösofageaalse ühenduskoha ehk gastrofageaalliiduse adenokartsinoom).
English: VEGFRhelps in the development of new blood vessels that supply the tumours.
Estonian: VEGFR soodustab kasvaja verevarustust tagavate uute veresoonte arenemist.
English: The most serious adverse effects reported (either of Cyramza alone or in combination with other cancer medicines) included gastrointestinal perforation (a hole that develops in the wall of the gut), severe gastrointestinal haemorrhage (bleeding from the gut) and arterial thromboembolic events
Estonian: Kõige raskemad teatatud kõrvalnähud (Cyramza ainuravimina või kombinatsioonis muude vähiravimitega manustamisel) on seedetrakti perforatsioon (sooleseina mulgustumine), gastrointestinaalne (seedetrakti) raske verejooks ja arteriaalse trombemboolia sündmused (trombist ja arterite ummistusest põhjustatud probleemid).
English: Cyramza also prolonged survival of patients with colorectal cancer, non-small cell lung cancer and hepatocellular carcinoma.
Estonian: Cyramza pikendas ka kolorektaalvähi, mitteväikerakk-kopsuvähi ja hepatotsellulaarse kartsinoomiga patsientide elumust.
English: Cyramza contains the active substance ramucirumab.
Estonian: Cyramza sisaldab toimeainena ramutsirumaabi.
English: What benefits of Cyramza have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Cyramza kasulikkus?
English: An overview of Cyramza and why it is authorised in the EU
Estonian: Ülevaade ravimist Cyramza ja ELis müügiloa väljastamise põhjendus
English: Cyramza is given by infusion (drip) into a vein.
Estonian: Cyramzat manustatakse veeniinfusioonina.
English: • non-small cell lung cancer that is advanced or has spread to other parts of the body.
Estonian: • kaugelearenenud või metastaatiline (levinud organismis ka mujale) mitteväikerakk-kopsuvähk.